Efficacia di nirsevimab nella prevenzione del VRS: sfide e prospettive di equità

1. Sumsuzzman DM, Wang Z, Langley JM, Moghadas SM. Realworld effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. Lancet Child Adolesc Health 2025;9(6):393-403. doi: 10.1016/S2352- 4642(25)00093-8 2. Munro APS, Drysdale SB, Cathie K, et al HARMONIE Study Group. 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. Lancet Child Adolesc Health 2025;9(6):404-12. doi: 10.1016/S2352- 4642(25)00102-6. 3. Barbas Del Buey JF, Íñigo Martínez J, Gutiérrez Rodríguez MÁ, et al. The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study. Front Public Health 2024;12:1441786. doi: 10.3389/ fpubh.2024.1441786. 4. Parada-Ricart E, Lledó-Gras N, Aragonès-Zabalza D, et al. Impact of Nirsevimab in Its Second Season on Respiratory Syncytial Virus and Non-RSV Admissions in Children Under 5. Pediatr Infect Dis J 2025 Nov 20. doi: 10.1097/INF.0000000000005059. 5. Cocchi E, Bloise S, Lorefice A, et al Multicentre study on nirsevimab: Bayesian analysis reveals persisting risk for preterm infants. BMJ Paediatr Open 2025;9(1):e003665. doi: 10.1136/bmjpo- 2025-003665. 6. Cocchi E, Bloise S, Lorefice A, et al. Nirsevimab Prophylaxis and Respiratory Syncytial Virus Hospitalizations Among Infants. JAMA Netw Open 2025;8(11):e2544679. doi: 10.1001/jamanetworkopen. 2025.44679. 7. Marchetti F. La profilassi dell’infezione da virus respiratorio sinciziale: dal dire al fare? Medico e Bambino 2024;43(4):211-2 doi: 10.53126/MEB43211. 8. Ceconi V, Guarino A, Russo R, Badolato R e le sezioni regionali SIP. Virus Respiratorio Sinciziale: strategia di prevenzione universale della bronchiolite nelle regioni italiane. Pediatria 2025;3: 10-12. 9. Villani A, Antilici L, Musolino AMC, et al. RSV bronchiolitis: a disease only for those who do not receive prophylaxis. Eur J Pediatr 2025;184(7):437. doi: 10.1007/s00431-025-06275-6. 10. Aricò MO, Accomando F, Trotta D, et al. Uneven Implementation of Nirsevimab Prophylaxis Resulted in Non-Uniform Reductions in RSV-Related Hospitalizations in Italy. Infect Dis Rep. 2025;17(5):115. doi: 10.3390/idr17050115. 11. European Centre for Disease Prevention and Control. Rapid scientific advice on protecting infants against respiratory syncytial virus disease for the European 2025/26 winter season - November 2025. Stockholm: ECDC, 2025. 12. Scott J, Abers MS, Marwah HK, et al. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026. N Engl J Med 2025 Oct 29. doi: 10.1056/NEJMsa2514268. 13. Wildenbeest JG, Bont L, Cianci D, et al BRICE Study Group. Impact of RSV hospitalization on healthcare costs, caregivers' productivity loss, and quality of life in children ≤ 2 years old in five European countries. Eur J Pediatr 2025;184(11):716. doi: 10.1007/s00431-025-06460-7. 14. Bonnel M, Perrella B, Vaux S, et al. Adherence to the nirsevimab immunization campaign: analysis of sociodemographic and medico-economic influences-single-centre prospective cohort study in France. Eur J Pediatr 2025;184(12):736. doi: 10.1007/ s00431-025-06581-z. 15. Pastor-Barriuso R, Núñez O, Monge S. Nirsevimab Effectiveness Study Collaborators. Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season. Euro Surveill 2025;30(6):2500040. doi: 10.2807/1560-7917. ES.2025.30.6.2500040. 16. Nieddu F, Vignoli M, Ferraro E, et al. Public health impact of nirsevimab and reduction of RSV hospitalisation in all infants: early real-world data from Tuscany (Italy) in the 2024-25 RSV season. Eur J Pediatr 2025;184(11):728. doi: 10.1007/s00431-025- 06588-6.